Online visual acuity test gains FDA clearance

Article

The web-based, self-guided software application is accessed through touchscreen mobile devices.

An online visual acuity test, the Visibly Digital Acuity Product (VDAP) (Visibly, Inc.), recently gained clearance from the Food and Drug Administration (FDA).1

The FDA described the VDAP as a web-based, self-guided software application that consumers can access using a touchscreen mobile device and internet-connected computer.

Adults aged 22 to 40 years who can perform an in-home self-test can use the test to help evaluate visual acuity, the FDA said.

According to the FDA website, “The application’s recommendations are intended to be supportive recommendations that will be used by an eye care provider, along with the patient’s medical history and profile, prior corrective eyewear prescriptions, and subjective vision data. This device does not provide screening or diagnosis of eye health or other disease and does not replace an eye health exam with a licensed provider.”

After the patient completes the test, the vision results are sent eye care professionals to evaluate and follow-up with the patient, for corrective lens prescription renewal online or referral for an in-person eye examination.

Reference
1. Larkin H. JAMA. Online visual acuity test cleared. 2022;328(13):1290. doi:10.1001/jama.2022.15443
Recent Videos
Spencer Johnson, OD, FAAO, overviews his talk on laser procedures at Optometry's Meeting
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
Raman Bhakhri, OD, FAAO, overviews his talk on medications' potential side effects on the retina with Optometry Times
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
© 2024 MJH Life Sciences

All rights reserved.